Pegloticase plus mycophenolate mofetil yields 86% response rate in uncontrolled gout

675629

Sumary of Pegloticase plus mycophenolate mofetil yields 86% response rate in uncontrolled gout:

  • Concomitant use of mycophenolate mofetil with pegloticase demonstrated clinically meaningful improvement in 86% of patients with uncontrolled gout, compared with pegloticase alone, according to data published in Arthritis &.
  • Concomitant mycophenolate mofetil can mitigate pegloticase immunogenic response in patients with gout, resulting in meaningfully improved serum urate at 12 and 24 weeks, according to data derived from Khanna PP, et al..
  • “The response [to pegloticase] is limited in some patients due the development of anti-pegloticase antibodies,”.
  • “In the rheumatology space, we’re familiar with this concept and have used a variety of [disease-modifying antirheumatic drugs] to minimize the development of antidrug antibodies (ADAs) and increase the efficacy of therapies..
  • Recently, there have been case series published on how methotrexate has successfully improved the response rate when used with pegloticase.”.
  • To analyze whether mycophenolate mofetil could prolong the efficacy of pegloticase (Krystexxa, Horizon Therapeutics) in patients with uncontrolled gout, Khanna and colleagues conducted a phase 2, proof-of-concept, placebo controlled randomized trial..
  • centers — with chronic refractory gout and serum urate levels of more than 6 mg/dL, and who had never received pegloticase or other uricase therapies..
  • Participants were randomized 3:1 to receive either 1,000 mg mycophenolate mofetil twice daily or placebo for 14 weeks, starting 2 weeks before, and while receiving, 8 mg of intravenous pegloticase biweekly for 24 weeks..
  • The primary endpoint was proportion of patients who sustained a serum urate level of 6 mg/dL or less at 12 weeks..
  • Secondary endpoints included 24‐week durability of the serum urate target, as well as the rate of adverse events..
  • According to the researchers, 86% of participants who received mycophenolate mofetil achieved the serum urate target of 6 mg/dL or less at 12 weeks, compared with 40% in the placebo group (P = .01)…

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close